Johnson & Johnson says its COVID-19 vaccine is 85 percent effective at preventing severe disease


Johnson & Johnson has unveiled some highly-anticipated data on its single-shot COVID-19 vaccine.
The company on Friday announced its vaccine candidate in a global trial was found to overall be 66 percent effective at preventing moderate to severe COVID-19, but 85 percent effective at preventing severe disease. In the United States, the company said the level of protection against moderate to severe illness was 72 percent, but in Latin America, it was 66 percent effective. It was also 57 percent effective in South Africa, where most of the COVID-19 cases were from the B.1.351 variant.
Johnson & Johnson's data had been particularly anticipated because, unlike the vaccines from Pfizer and Moderna that have been approved in the United States, this candidate only requires one shot. The overall 66 percent efficacy rate wasn't as high as with either of those vaccines, which were each found to be about 95 percent effective, but that's still above the 50 percent level the FDA requires.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
University of Wisconsin School of Medicine and Public Health vaccine expert Jonathan Temte also told The Washington Post the Johnson & Johnson vaccine could still be a "game changer," especially since it can be stored at refrigerator temperature.
"Back in July and August, I was hoping we would see a vaccine that was 60 percent effective — in my mind, that would be great," Temte told the Post. "And now we have had two that have hit the ball out of the park and set expectations spectacularly high, and that's not fair because we don't need a home run all the times we're up to bat."
Johnson & Johnson also noted that in the the trial, the vaccine provided "complete protection against COVID-related hospitalization and death." The company plans to file with the Food and Drug Administration for emergency authorization within a week, The Associated Press reports, and it says it "expects to have product available to ship immediately following authorization."
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.
-
Sail in style onboard the brand-new Explora II
The Week Recommends Hit the high seas on a luxury cruise from Barcelona to Rome
-
Is the EU funding Russia more than Ukraine?
The Explainer EU remains largest importer of Russian fossil fuels despite sanctions aimed at crippling Kremlin's war effort
-
Posh crisps: an 'elite' tier of snacking
The Week Recommends Hand-cooked and dusted in 'decadent' flavours, the humble potato chip is being elevated to new levels
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia
-
Measles outbreak spreads, as does RFK Jr.'s influence
Speed Read The outbreak centered in Texas has grown to at least three states and Health Secretary Robert F. Kennedy Jr. is promoting unproven treatments
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows